Navigation Links
YM BioSciences provides update on AeroLEF(TM) clinical development program
Date:1/17/2008

MISSISSAUGA, ON, Jan. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the Company that the Phase II Acute Pain Study (AP5) of AeroLEF(TM) for which FDA clearance was announced on June 27, 2007, upon re-review of data from the IND submission, has been placed on clinical hold. The FDA has requested additional safety information on specific patients in previous clinical studies. The additional requested data is limited to a small group of patients that experienced oxygen desaturation, a class effect of opioids including fentanyl. The Company will conduct a subgroup analysis on these patients. To date, no patients have been dosed in the US AP5 study and there are no other clinical trials involving AeroLEF(TM) currently ongoing.

"We are confident that we can provide the information the FDA has requested in a timely manner," said David Allan, Chairman and CEO of YM BioSciences. "We appreciate that the FDA has to ensure that any risk to patients during clinical trials is minimized and we understand their caution with opioid-based therapeutics."

Dr. Diana Pliura, Executive Vice President, AeroLEF(TM) added, "Data reported in May 2007 from our successful randomized Phase 2b trial demonstrated that patients had a statistical and clinical benefit from AeroLEF(TM). We remain strongly committed to the clinical development of this unique product."

YM BioSciences also reported that it held its scheduled End-of-Phase 2 (EoP2) meeting with the FDA on January 16, 2007 as planned.

YM
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
(Date:9/15/2014)... Research and Markets has announced the ... by Services, by Technology, by Application - Global Forecast to ... Exome Sequencing (WES) is next-generation technology used for strategically sequencing ... exome, which is the total of all exons of an ... actually converted into proteins after translation. It is responsible for ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
(Date:9/15/2014)... , Sept. 15, 2014  The second annual ... celebrated October 12-18. A joint initiative of the ... member companies , IPAW is designed to: ... , Recognize the contributions of plasma donors in saving ... plasma protein therapies and rare diseases ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... Sinovac Biotech Ltd. (Amex:,SVA), a leading provider ... today that the Annual General Meeting of ... postponed due the geographical,nature of its shareholders ... materials. The Company is currently working to ...
... LLC announced,today that two new managing directors have ... firm in July 2007 as Managing Director and,Associate ... portfolios of potential investments for Third,Security,s funds, and ... and develop their own intellectual property positions. Mr. ...
... Aug. 20 Advanced Cell,Technology, Inc. (OTC Bulletin ... conditions, it plans to privately offer up to ... timing of the,closing of the offering will be ... are expected to be used to fund working ...
Cached Biology Technology:Sinovac Announces Postponement of Annual General Meeting 2Third Security, LLC Hires Two New Managing Directors 2Advanced Cell Technology Announces Proposed Financing 2Advanced Cell Technology Announces Proposed Financing 3
(Date:9/15/2014)... West Africa, which has claimed more than 2000 lives, ... the molecular biology of the virus that could be ... to treat or prevent Ebola hemorrhagic fever. Now, a ... under the leadership of Dr Dan Engel, a virologist, ... obtained the crystal structure of a key protein involved ...
(Date:9/15/2014)... long and weighing as much as 170 tons, the blue ... far the heaviest living thing ever seen on Earth. So ... the tiniest fish larvae, which measure millimeters in length and ... , Not so fast, says L. Mahadevan, the Lola ... Evolutionary Biology, and of Physics. , Using simple hydrodynamics, ...
(Date:9/15/2014)... teeming with life it,s not what comes to mind ... time evidence of Doncaster,s 310-million-year-old past, including a fossilised shark ... , Some of the fossilised plants and creatures may even ... case, several horseshoe crabs and some previously unrecorded seed pods ... rocks that formed within the coal and shale deposits in ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2The science behind swimming 2The science behind swimming 3'Jaws' lived in Doncaster 2
... change is already having a detectable impact on birds ... team publishing their findings to create the world,s first ... a continental scale. Published in the journal ... Royal Society for the Protection of Birds have shown ...
... climate change projected this century for Oregon,s Upper ... supplies, buildings, transportation systems, human health, forests, and ... by the University of Oregon,s Climate Leadership Initiative ... Policy. The authors say that extensive efforts ...
... DNA in the nucleus of each of our cells is converted ... serve as coding templates for the synthesis of proteins. Of the ... scant few are known: they inhibit the activity of genes or ... within cells. What the rest of them do within cells is ...
Cached Biology News:Climate change affecting Europe's birds now, say researchers 2Climate change affecting Europe's birds now, say researchers 3Eugene-Springfield face Upper Willamette climate threats 2Eugene-Springfield face Upper Willamette climate threats 3Eugene-Springfield face Upper Willamette climate threats 4CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 2CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 3
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: